Neumora navacaprant fails Phase 3 as EnGene cuts 50% of staff

Neumora discontinues navacaprant after two Phase 3 failures

Key Takeaways

• Neumora Therapeutics is discontinuing navacaprant development following two Phase 3 trial failures.
• The biotech is laying off 35% of its workforce in response to the program termination.
• In one late-stage trial, navacaprant was less effective than placebo after six weeks in reducing depression symptoms.
• Neumora is shifting research focus toward Alzheimer's disease and obesity following the depression program exit.
• Navacaprant is a selective kappa opioid receptor antagonist studied for major depressive disorder.

IntelligenceRegulatory Impact▾

FDA and EMA decisions frame this story. Regulatory relevance is medium for depression, with navacaprant most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.

The Development

Neumora Therapeutics is discontinuing development of navacaprant, its lead depression candidate, following two Phase 3 trial failures. The Watertown-based biotech has also initiated a workforce reduction tied to the program termination. The company is laying off 35% of its employees and redirecting research efforts toward other therapeutic areas.

In one late-stage trial, navacaprant was found to be less effective than a placebo in reducing depression symptoms after six weeks of treatment. The program had included testing in both major depressive disorder and bipolar II disorder-related major depressive episode before the Phase 3 setbacks prompted discontinuation. The clinical setbacks underscore the challenges facing depression drug development, where placebo response rates remain high and clinical efficacy thresholds demand consistent superiority across multiple trials.

IntelligenceCompetitive Intelligence▾

Competitive pressure is high. Neumora Therapeutics, EnGene, and J&J reshape positioning, formulary leverage, and partnership options. Benchmark pipeline differentiation and regional market access assumptions against this development.

Clinical Trial Program: What Was Tested?

Navacaprant is a novel and highly selective kappa opioid receptor antagonist studied in adults with major depressive disorder. The clinical development program included Phase 3 trials registered on ClinicalTrials.gov:

• NCT06029439: Study to Assess the Safety and Effectiveness of NMRA-335140-501 (Phase 3; Active, Not Recruiting)
• NCT06058013: Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder (Phase 3; Active, Not Recruiting)
• NCT06058039: Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder (Phase 3; Active, Not Recruiting)
• NCT06029426: Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder (Phase 3; Completed)

The program also included a completed Phase 2 study (NCT06429722) evaluating navacaprant in major depressive episode associated with bipolar II disorder. The breadth of the clinical portfolio reflects Neumora's earlier confidence in the compound's potential across depression subtypes, though the Phase 3 failures in the primary indication prompted the decision to discontinue development entirely.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance medium for depression. Expect implications for pricing, access, and launch sequencing.

Strategic Realignment: What Comes Next?

Following the discontinuation of its depression drug program, Neumora Therapeutics is shifting its research focus toward Alzheimer's disease and obesity. The company's decision to exit the navacaprant program represents a significant pivot in resource allocation and pipeline strategy for the biotech. Neumora filed an 8-K with the SEC on June 15, 2026, disclosing the program discontinuation and workforce reduction. The reallocation of research efforts to neurodegenerative and metabolic indications signals a strategic recalibration as the company seeks to deploy remaining capital and personnel toward therapeutic areas where its platform may find clearer clinical differentiation.

Frequently Asked Questions